TotalMarketCap

Cullinan Therapeutics

CGEMNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$704.040 M

$10.94 -12.41%

Close of 6 Nov 2026

As of 6 Nov 2026, Cullinan Therapeutics (CGEM) has a market capitalization of $704.0M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$219.9M

Loss-making

Shares outstanding

64,354,694

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #49MeiraGTxMGTX$818.2M
  2. #50Prime MedicinePRME$806.2M
  3. #51Cullinan TherapeuticsCGEM$704.0M
  4. #52Sana BiotechnologySANA$697.5M
  5. #53Solid BiosciencesSLDB$686.4M

What if Cullinan Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$438,769.45

Per share 40,107× higher

Bitcoin $1.53T

$23,741.05

Per share 2,170× higher

Apple $5.02T

$77,939.65

Per share 7,124× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for Cullinan Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.